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Abstract
Doxorubicin complexation with the transition metal manganese (Mn2 + ) has been characterized, differentiating between the formation of a
doxorubicin–metal complex and doxorubicin fibrous-bundle aggregates typically generated following ion gradient-based loading procedures
that rely on liposome encapsulated citrate or sulfate salts. The physical and chemical characteristics of the encapsulated drug were assessed
using cryo-electron microscopy, circular dichroism (CD) and absorbance spectrophotometric analysis. In addition, in vitro and in vivo drug
loading and release characteristics of the liposomal formulations were investigated. Finally, the internal pH after drug loading was measured
with the aim of linking formation of the Mn2 + complex to the presence or absence of a transmembrane pH gradient. Doxorubicin was
encapsulated into either 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)/cholesterol (Chol) or 1,2-distearoyl-sn-glycero-3-phospho-
choline (DSPC)/Chol liposomes, where the entrapped salts were citrate, MnSO4 or MnCl2. In response to a pH gradient or a Mn
2 + ion
gradient, doxorubicin accumulated inside to achieve a drug-to-lipid ratio of approximately 0.2:1 (wt/wt). Absorbance and CD spectra of
doxorubicin in the presence of Mn2 + suggested that there are two distinct structures captured within the liposomes. In the absence of added
ionophore A23187, drug loading is initiated on the basis of an established pH gradient; however, efficient drug uptake is not dependent on
maintenance of the pH gradient. Drug release from DMPC/Chol is comparable regardless of whether doxorubicin is entrapped as a citrate-
based aggregate or a Mn2 + complex. However, in vivo drug release from DSPC/Chol liposomes indicate less than 5% or greater than 50%
drug loss over a 24-h time course when the drug was encapsulated as an aggregate or a Mn2 + complex, respectively. These studies define a
method for entrapping drugs possessing coordination sites capable of complexing transition metals and suggest that drug release is dependent
on lipid composition, internal pH, as well as the nature of the crystalline precipitate, which forms following encapsulation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes as model closed membrane systems have
proven to be a valuable tool to characterize and define the
functional roles of lipids. Liposomes have facilitated studies
on lipid mobility, lipid phase behaviour and membrane
permeability. The latter studies were especially insightful
in terms of resolving solute permeability [1], ion gradient
formation [2] and formation and stability of transmembrane
electrochemical potentials [3]. An example of how these
biochemical and biophysical assessments helped to define
liposomes as drug carriers is illustrated by the observations
of Nichols and Deamer [4], who demonstrated that lip-
osomal systems possessing an acidic interior had the ability
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to sequester catecholamines. Their studies were focused on
possible mechanisms of catecholamine storage in secretory
organelles but their results had far reaching effects. As first
noted by Bally et al. [5], the accumulation of hydrophobic
cations and lipophilic weak bases provided an important
method for loading therapeutic agents into preformed mem-
brane-bound vesicles.
Encapsulation procedures that have been developed for
amphipathic drugs with protonizable amine functions
involve the addition of drug to preformed liposomes pos-
sessing a pH gradient or an ion gradient capable of gen-
erating a pH gradient [6,7]. Encapsulation relies on the
neutral form of the drug penetrating through the lipid
bilayer, where the drug then encounters an acidic environ-
ment. The drug becomes protonated, charged and thus is
retained within the liposome interior [8,9]. As more of the
neutral form of the drug enters the liposome and is proto-
nated, the amount of the neutral form on the exterior of
liposomes will be depleted as the drug equilibrates across
the membrane according to the Henderson–Hasselbalch
equation. Protons (H + ) are (relative to other cations) highly
permeable across the lipid bilayer and will diffuse outward
creating an electrochemical gradient [10] but this process
will cease at a certain point due to the presence of this
electrochemical gradient (DW negative inside). Alterna-
tively, an electrochemical gradient can promote pH gradient
formation [3]. For example, when liposomes are prepared in
a potassium (K + )-based buffer (pH 7.4) and the external
solution is replaced with a buffered (pH 7.4) NaCl solution,
addition of the K + ionophore valinomycin shuttles K +
outside the liposome, creating an 150 mV electrochemical
gradient (DW, interior negative) [10]. Protons (H + ) readily
cross the lipid bilayer into the interior, in response to the DW
gradient and a pH gradient is thus established.
By virtue of being able to exchange selected cations, other
ionophores can also establish pH gradients. Several research-
ers [5,11–13] have used nigericin (K + ) ionophore and
A23187 (divalent cation ionophore) to exchange specific
cations for either one or two protons, respectively. When
liposomes possessing a transmembrane salt gradient are
incubated with the specific ionophore, the ionophores are
able to facilitate the outward movement of cations for the
inward movement of hydrogen ions, thereby creating a pH
gradient. Regardless of the method used to generate the pH
gradient, the extent of drug loading and the stability of the
resulting drug loaded preparation are dependent on several
factors, including drug-to-lipid ratios, entrapped buffer com-
position and membrane lipid composition. These factors are
thought to be associated with maintenance of the pH gradient
following drug loading and following in vivo administration.
It is known that gradient-based trapping procedures can
result in entrapped drug levels that greatly exceed those
predicted on the basis of an equilibrium established in
accordance to the measured proton gradient. This is exem-
plified by the anthracycline doxorubicin. It has been argued
that the higher than predicted drug levels can be accounted for
by calculations that consider drug membrane partitioning
[14]. Themore generally accepted explanation is based on the
formation of an insoluble drug precipitate [15–18]. Cryo-
transmission electron microscopy (cTEM) reveals doxorubi-
cin precipitates as fibrous-bundle aggregates in both citrate
and sulfate-containing liposomes [15,17]. Recently, certain
researchers have suggested that the physical state of doxor-
ubicin may also play a role in drug release [18]. It is argued
here that attempts to use ion gradient-based procedures to
prepare drug-loaded liposomes exhibiting optimized drug
pay-out characteristics have been stymied, in part, by our
lack of understanding of the physical and chemical character-
istics of the encapsulated drug. For this reason, studies
evaluating the role of doxorubicin precipitation in controlling
the rate of drug release in vivo have been conducted. Our
investigation differentiates between a drug loading method
that results in formation of a transition metal–doxorubicin
complex as compared to either citrate- or sulfate-based
fibrous aggregates, and suggests that drug release from lip-
osomes is dependent on a combination of internal pH,
membrane lipid composition as well as the nature of the drug
precipitate.
2. Materials and methods
2.1. Materials
Doxorubicin hydrochloride for injection (Faulding Que-
bec, Canada) was purchased from the BC Cancer Agency.
1,2,-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and
1,2 distearoyl-sn-glycero-3-phosphocholine (DSPC) was
obtained from Northern Lipids Incorporated (Vancouver,
BC, Canada). Cholesterol (Chol), the A23187, Sephadex
G-50 and all other chemicals were obtained from the Sigma
Chemical Company (St. Louis, MO, USA). [3H]-cholesteryl
hexadecyl ether (3H-CHE) was obtained from NEN Life
Science Products, (Boston, MA, USA) and 14C-methyl-
amine hydrochloride from Amersham Pharmacia Biotech.
(Oakville, Canada). Pico-Fluor15 and 40 scintillation fluid
was purchased from Canberra-Packard (Meriden, CT). CD-
1 mice (8–10 weeks of age) were obtained from Charles
River Laboratories (St. Constant, Quebec, Canada). Fetal
bovine serum was bought from Hyclone Laboratories
(Logan, UT).
2.2. Methods: preparation of liposomes
All liposomes were made from either DMPC/Chol
(55:45) mole per mole (mol/mol) or DSPC/Chol (55:45)
(mol/mol) and were prepared by extrusion methods. Lipids,
at the indicated ratios, were dissolved in chloroform, and the
3H-CHE was added to achieve approximately 10 ACi/100
mg lipid. The chloroform was removed under a gentle
stream of nitrogen gas and, subsequently, the lipid samples
were placed under a high vacuum for a time period of at
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least 4 h to remove any residual solvent. The dried samples
were hydrated (such that the final lipid concentration was
approximately 100 mg/ml) with 300 mM citrate buffer, 300
mM MnSO4 or 300 mM MnCl2; adjusted to pH 3.5 by
addition of hydrochloric acid. Following hydration, the
multilamellar vesicles (MLVs) were subjected to five
freeze-and-thaw cycles (freezing in liquid nitrogen and
thawing at 40jC). The resulting frozen and thawed MLVs
were prepared to optimize the salt distribution across the
lipid bilayers [19]. The MLVs were extruded 10 times
through stacked polycarbonate filters of 0.1 and 0.08 Am
pore size at 40jC using a water-jacketed ExtruderTM
(Northern Lipids). The mean size distribution of all lip-
osome preparations was determined using a Nicomp Sub-
micron Particle Sizer Model 270 (Pacific Scientific, Santa
Barbara, CA) operating at 632.8 nm. The resulting liposome
preparations typically exhibited an average diameter of
approximately 100–120 nm. All liposomes, except those
used for cTEM analysis and circular dichroism (CD) studies
were radiolabeled. For these experiments, the phospholipid
was quantitated using the Fiske and Subbarow [20] phos-
phate assay. Briefly, 700 Al of 70% perchloric acid was
added to lipid samples and heated to approximately 180–
200jC for 2 h until the samples were colourless. Samples
were cooled and 700 Al of Fiske reagent and 7 ml of
ammonium molybdate was added and samples were sub-
sequently reheated again to 100jC for 20 min. Samples
were cooled to room temperature and the absorbance was
read at 820 nm.
2.3. Preparation of ion gradients for doxorubicin encapsu-
lation
Large unilamellar liposomes in the indicated buffers were
fractionated on Sephadex G-50 columns (1 ml sample vol-
umes were placed on columns with at least a 20 ml column
bed) equilibrated with various buffers at pH 7.5. The buffers
used for the external environment included 25 mM HEPES/
150 mM NaCl (HBS) for the liposomes with encapsulated
300 mM citrate and 300 mM sucrose/20 mMHEPES/15 mM
EDTA (SHE) for the liposomes with encapsulated MnSO4
and MnCl2. The manganese sulfate-based procedure for
doxorubicin loading was a modification of the method
described by Cheung et al. [11]. In particular, it should be
noted that the solubility of 300 mMMnSO4 is highly variable
under the pH conditions described in the original procedure,
presumably resulting in the formation of Mn(OH)2(S). In the
studies reported here, liposomes were prepared in a 300 mM
MnSO4 (andMnCl2) solution at a pH of 3.5; solutions that are
stable for months at room temperature.
2.4. Drug loading and release
Following formation of the salt gradients as described
above, the liposome lipid concentration was adjusted to
10 mg/ml and, subsequently, doxorubicin was added to
achieve a drug-to-lipid ratio (wt/wt) of 0.2:1 at 20, 40
and 60jC. The accumulation of doxorubicin into lip-
osomes was determined at the indicated time points by
removing 100 Al aliquots and separating unencapsulated
drug from encapsulated drug on 1 ml Sephadex G-50
(medium) spin columns equilibrated with the appropriate
buffer. The concentration of doxorubicin in the excluded
fraction was determined by measuring absorbance (at 480
nm) of a solution consisting of the sample, adjusted to 100
Al with HBS or SHE, to which 900 Al of 1% Triton X-100
was added. Prior to assessing absorbance at 480 nm, the
sample was placed in >90jC water bath until the cloud
point of the detergent was observed. Liposome lipid con-
centrations were determined by adding a small aliquot of
the excluded fraction to 5 ml of scintillation cocktail, where
the radioactivity of the sample was subsequently deter-
mined by scintillation counting with the Packard 1900TR
Liquid Scintillation Analyzer.
The in vitro doxorubicin release assay used liposomes
with a drug-to-lipid ratio of 0.2:1 (wt/wt). Samples were
mixed with fetal bovine serum such that the final lipid
concentration was 2 mg/ml and the final serum concentra-
tion was 50%. These samples were incubated at 37jC and at
the indicated time-points, 100 Al aliquots were placed onto 1
ml spin columns. The liposome lipid concentration was
quantitated via liquid scintillation techniques and encapsu-
lated doxorubicin was assayed as described above.
For the in vivo studies assessing doxorubicin release,
drug-loaded liposomes (0.2:1 drug-to-lipid ratio, wt/wt)
were adjusted to a lipid concentration required to administer
a 100 mg/kg liposomal lipid or 20 mg/kg doxorubicin dose
in an injection volume of 200 Al. This dose translates to
approximately 45.7 Amol Mn2 + /kg of for DMPC–Chol
liposomes or 40.95 Amol Mn2 + /kg for DSPC–Chol lip-
osomes, which are well below the acute LD50 value of 272
Amol Mn2 + /kg (95% confidence limits: 227–326 Amol
Mn2 + /kg) [21] determined for mice. Various formulations
were injected intravenously (i.v., via the lateral tail vein)
into 20–22 g female CD-1 mice. At 1, 4 and 24 h after
injection, the animals were terminated by CO2 asphyxiation
and blood was collected by cardiac puncture and placed into
EDTA coated microtainers. Plasma was prepared by cen-
trifuging the blood samples at f 500 g for 10 min.
Plasma was removed carefully such that the buffy coat
was not disturbed and collected into Eppendorf tubes. The
plasma lipid concentrations were measured on the basis of
the incorporated 3H-CHE marker, which is nonexchange-
able and nonmetabolizable [22]. Samples of 50–100 Al
were mixed with 5 ml of PicoFluor-40 scintillation cocktail
prior to assessing the radioactivity.
Plasma doxorubicin levels were determined following
extraction of the drug from plasma using a procedure
involving addition of 800 Al of 10% SDS and 10 mM
H2SO4 to a plasma sample diluted to 200 Al in HBS or SHE.
These samples were briefly vortexed prior to addition of 2
ml of a 1:1 isopropanol–chloroform mixture. This sample
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was again vortexed vigorously prior to freezing in a
 80jC freezer for at least 4 h to help precipitate out plasma
proteins. The samples were thawed to room temperature and
then centrifuged at 2000 g for 15 min to separate the
organic layer (bottom layer that contains doxorubicin) from
the aqueous layer and protein interface. The amount of
doxorubicin associated fluorescence in the organic phase
was determined using a Perkin Elmer LS50B luminescence
spectrometer using an excitation wavelength of 470 nm (slit
width = 2.5) and an emission wavelength of 550 nm (slit
width = 10). The fluorescence readings were compared to a
standard curve of doxorubicin, which was prepared using
known amounts of doxorubicin that were extracted into an
organic phase using the identical procedure used for the
unknowns.
All animal studies were done according to procedures
approved by the University of British Columbia Animal
Care Committee. These studies meet the requirements out-
lined in the current guidelines for animal use established by
the Canadian Council of Animal Care.
To assess the stability of doxorubicin within the man-
ganese-containing liposomes and confirm that manganese is
not inducing doxorubicin degradation, high-performance
liquid chromatography (HPLC) was used to resolve intact
doxorubicin. Drug-loaded liposomes (0.2:1 drug-to-lipid
ratio, wt/wt) were incubated and at the indicated time-
points, 100 Al aliquots were placed onto 1 ml spin columns.
The liposome lipid concentration was quantitated via liquid
scintillation techniques and encapsulated doxorubicin was
assayed using HPLC. HPLC was done using a Waters
Alliance 2690 HPLC system with Waters 474 Fluorescence
Detector set at an excitation wavelength of 480 nm and
emission wavelength of 580 nm, controlled by Waters
Millennium 32 software. Fifty microlitres of sample was
injected onto a Waters Symmetry C18 column, 4.6 75 mm
using a mobile phase of 78% 16 mM ammonium formate
buffer pH 3.5, 15% acetone and 7% isopropanol at 1 ml/
min. Column temperature was maintained at 40jC and
samples at 5jC.
2.5. pH gradient determination
Transmembrane pH gradients were monitored employing
[14C]-methylamine. Briefly, [14C]-methylamine (0.5 ACi/ml)
was added to a liposome solution containing < 10 mg/ml of
lipid. After 15 min, 150 Al aliquots were passed down 1 ml
Sephadex G-50 columns at 60jC equilibrated in HBS to
remove unencapsulated methylamine (column run time of
3–5 min). Lipid and methylamine concentrations before and
after column chromatography were determined by scintilla-
tion counting. The transmembrane pH gradient was then
calculated according to the relationship:
DpH ¼ logf½Hþinside=½Hþoutsideg
¼ logf½methylamineinside=½methylamineoutsideg
It should be noted that under the conditions employed, the
exterior pH did not change during the uptake process.
2.6. Absorption and CD spectra
To verify if manganese was indeed binding to doxor-
ubicin, changes in doxorubicin absorption spectra under
various proton and metal concentrations was determined
using a Hewlett Packard 8453 UV–Visible Spectroscopy
System (cell path length = 1.00 cm). Doxorubicin was
added to buffers at pH 6 (100 mM MES), pH 8 (100
mM HEPES), pH 9 (100 mM CHES), pH 10 (100 mM
CAPS), pH 11 (100 mM CAPS) and pH 13 (100 mM
glycine + 100 mM NaCl) at a constant doxorubicin concen-
tration of 86 AM. At the concentrations used MnSO4,
MnSO4 had a very low solubility in basic solutions. In
order to circumvent this problem, MnSO4 (S) was added to
buffered solutions containing 100 mM HEPES at pH 8 and
vigorously vortexed. Due to the formation of Mn(OH)2
precipitate (within 12 h), absorbance readings were done
immediately, well before the visible formation of the
precipitate. To monitor electronic state changes within
doxorubicin-loaded liposomes, CD spectra of each drug
loaded liposome preparation were analysed. CD measure-
ments were obtained using the Jasco J-720 spectropolarim-
eter, which was calibrated using 0.06% (w/v) ammonium-
D-10-camphorsulfonate. All spectra were recorded using a
0.1 cm cell and the following parameters: k = 220–750 nm,
step resolution = 1 nm, speed = 20 nm/min, response = 0.25
s, band width = 1.0 nm. Results are expressed in differential
molar CD absorption De (M  1 cm 1),
De ¼ h=32980 C  l
where h =molar ellipticity, C =molar concentration, and
l = path length of cell in centimeters.
2.7. Cryo-transmission electron microscopy
DMPC/Chol liposomes were prepared as described
above without the 3H-CHE lipid marker. Liposomes were
loaded with doxorubicin at a 0.2:1 drug-to-lipid ratio (wt/
wt). In a chamber of controlled temperature (25jC) and
humidity, 1–2 Al of liposome sample (before or after the
addition of drug) was added and blotted onto copper grids
coated with a cellulose acetate butyrate polymer. The
samples were quickly vitrified by plunging into liquid
ethane and transferred to liquid nitrogen keeping the sample
below 108 K, therefore minimizing sample pertubation and
the formation of ice crystals. The grid was transferred to a
Zeiss EM902 transmission electron microscope where
observations were made in a zero-loss bright-field mode
and an accelerating voltage = 80 kV.
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3. Results
3.1. The encapsulation of doxorubicin into DMPC/Chol
liposomes using the citrate loading procedure or the
manganese sulfate loading procedure
The first objective of this study was to compare the
manganese sulfate loading procedure [11,13] to the citrate-
based loading method, using doxorubicin as a model drug.
The citrate loading procedure relies on an established pH
gradient across the liposome bilayer and the use of encap-
sulated 300 mM citrate as a buffer to minimize changes in
interior pH as doxorubicin redistributes across the liposomal
membrane according to the transmembrane gradient (inte-
rior acidic) (see Fig. 1A). It should be noted that when
doxorubicin is encapsulated using this method, the resulting
drug-loaded liposomes appear as a bright opaque orange
colour. When doxorubicin is encapsulated using the man-
ganese sulfate-based loading procedure described by
Cheung et al. [11] (Fig. 1B,C), a pH and a metal ion
gradient are present across the liposome. Similar to the
citrate-based loading method doxorubicin, it is anticipated
that the neutral form of the drug crosses the lipid bilayer.
Subsequently, the amine group becomes protonated, result-
ing in an increase in the liposomes’ interior pH. In order to
maintain the interior pH, other researchers [11] have used
the divalent cation ionophore A23187 (an electro-neutral
ionophore capable of translocating a divalent cation for the
exchange of two hydrogen ions). A23187 shuttles protons to
the vesicle interior in exchange for Mn2 + ions [23], which
are subsequently chelated by EDTA contained in the exte-
rior buffer (Fig. 1C). The opaque orange colour of the
resulting drug loaded liposomes is visually comparable to
solutions prepared using the citrate-based loading method
and free doxorubicin at pH 3–7. Perhaps most interestingly,
in the absence of the ionophore (Fig. 1B), doxorubicin
loading is accompanied by a change in the colour of the
solution from orange to an opaque royal purple colour.
To compare the three different loading methods
described in Fig. 1, the accumulation of doxorubicin into
DMPC/Chol liposomes was determined as a function of
temperature and time. The drug loading parameters were
determined under conditions where the drug and liposomes
were mixed at a drug-to-lipid ratio (wt/wt) of 0.2:1 and the
final liposome lipid concentration was adjusted to 10 mM
for each method. The doxorubicin loading data, summar-
ized in Fig. 2, indicate that the loading attributes for all
three methods are comparable at all temperatures evaluated.
At 20jC, the drug-to-lipid ratio does not change over the
entire time course, a result consistent with drug membrane
partitioning but no accumulation. Optimal loading occurs
when the incubation temperature is adjusted to 60jC, where
>95% of the added doxorubicin is encapsulated within the
liposomes within 5 min.
To assess the stability of doxorubicin within the man-
ganese-containing liposomes and confirm that manganese
is not inducing doxorubicin degradation, HPLC was used
to resolve intact doxorubicin (Fig. 3). Doxorubicin loaded
DMPC/Chol and DSPC/Chol liposomes (0.2:1 drug-to-
lipid ratio, wt/wt), were prepared using the citrate or the
manganese sulfate-based loading procedures. Changes in
drug-to-lipid ratios were used to calculate the percent (%)
of remaining doxorubicin, measured at various time points
over a 48-h time course. In both the DMPC/Chol (Fig. 3A)
and DSPC/Chol (Figure 3B) liposomes, total intact doxor-
ubicin concentrations within citrate and manganese-con-
taining liposomes were comparable over the time course.
There was approximately a 9% greater level of intact
doxorubicin in citrate as compared to the manganese
loaded DMPC/Chol liposomes and a 10% greater level
of intact doxorubicin in the citrate as compared to the
manganese loaded DSPC/Chol liposomes at the 48 h
timepoint. It is important to note that the methods
described are consistent with a reconstitution procedure
that involves encapsulation of the drug in preformed lip-
osomes just prior to drug administration. This procedure
Fig. 1. Methods of doxorubicin encapsulation into liposomes exhibiting the
indicated gradients: (A) liposomes prepared in 300 mM citrate buffer, pH
3.5, and outside buffer exchanged to HBS at pH 7.5, (B) liposomes
prepared in 300 mM manganese sulfate, pH 3.5, and outside buffer is
exchanged to 300 mM sucrose/20 mM HEPES/15 mM EDTA at pH 7.5 and
(C) which is identical to (B) except that the ionophore A23187 is added to
the liposomes prior to doxorubicin addition.
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has been validated in the clinic for formulations of doxo-
rubicin and vincristine [36].
3.2. Cryo-transmission electron microscopic analysis of the
drug-loaded liposomes
Doxorubicin, when loaded into sulfate or citrate-contain-
ing liposomes with an acidic interior (pH < 5), will form a
precipitate, particularly when the final drug-to-lipid ratio is
in excess of 0.05:1 (wt/wt) [2,15,17,18]. One of the best
methods to evaluate formation of the drug precipitate within
liposomes relies on use of cTEM [2,24]. For this reason,
cryo-electron micrographs of the DMPC/Chol liposomal
formulations, before and after drug loading, were obtained
and representative images are shown in Fig. 4. The image
shown in Fig. 4IA is of liposomes prepared in a 300 mM
citrate buffer (pH 3.5) after the exterior buffer was
exchanged to HBS (pH 7.5). These liposomes appear to be
mostly spherical and uniform in size ranging around 120 nm;
a value that is consistent with the size determined by light
scattering analysis (see Methods). Following accumulation
of doxorubicin to a final drug-to-lipid ratio of 0.2:1 (wt/wt), a
precipitate is readily visible within the vesicular structures
(Fig. 4IIA). The doxorubicin bundles appear as linear or
circular structures, and drug precipitation can induce a
change in the shape of the liposomes, resulting in a ‘‘coffee
bean’’ like appearance.
Liposomes prepared in 300 mMMnSO4 with the exterior
buffer exchanged to the EDTA-containing pH 7.5 buffer,
appear as elongated and tubular structures (Fig. 4IB,IC) in
comparison to the citrate-containing liposomes (Fig. 4IA).
When these liposomes are loaded with doxorubicin using
A23187, the resulting liposomes have a pronounced elon-
gated structure and what appears to be a linear bundle of
Fig. 3. The stability of doxorubicin within DMPC/Chol (55:45) and DSPC/
Chol liposomes containing either citrate or manganese sulfate. DMPC/Chol
(A) or DSPC/Chol (B) liposomes were loaded with doxorubicin to achieve a
final drug-to-lipid ratio of 0.2:1 (wt/wt) using the citrate (white bars) or the
manganese sulfate (black bars) procedures as previously described in
Methods. At the indicated time points, the drug and liposomal lipid
concentrations were measured after fractionating samples on a 1 ml spin
column as described in the Methods. Doxorubicin was measured using
HPLC to provide a measure of intact drug. These data were used to calculate
the percentage of remaining doxorubicin at various time points. Data points
represent the mean of data obtained from six separate experiments and the
error bars indicate the standard deviation for each data point.
Fig. 2. Doxorubicin encapsulation in DMPC/Chol (55:45) liposomes using
the three loading methods, illustrated in Fig. 1, and based on liposomes
prepared using (A) citrate loading procedure, (B) the manganese sulfate
loading procedure or, (C) the manganese sulfate loading procedure with the
A23187 ionophore. Liposomes were prepared as described in Methods and
the outer buffers were exchanged using column chromatography in order to
create a pH or a Mn2 + gradient. For the MnSO4 loading procedure, the
A23187 was added and incubated 5 min prior to the addition of drug.
Doxorubicin was added to the liposomes to achieve a 0.2:1 drug-to-lipid
ratio (wt/wt) and incubated at either 20jC (n), 40jC (.) or 60jC (E). At
the indicated time points, aliquots were fractionated on 1 ml spin columns
to separate encapsulated drug (collected in the void volume) from
unencapsulated drug. Lipid concentrations were determined using 3H-
CHE and doxorubicin was quantitated by reading the A480 of a detergent
solubilized sample as described in the Methods. Data points represent the
mean drug-to-lipid ratios of at least three replicate experiments and the error
bars indicate the standard deviation.
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precipitated doxorubicin within the core. In contrast, there is
no obvious precipitate inside doxorubicin-loaded liposomes
prepared in the absence of A23187. The cryo-electron
microscopic images of these liposomes reveal a stippled
and diffuse morphology within the liposome core (Fig.
4IIB). These results clearly indicate significant differences
in the doxorubicin-containing liposomes prepared with and
without A23187. The next series of experiments were
designed to assess the role of entrapped sulfate and interior
pH on the formation of the doxorubicin precipitate.
3.3. The encapsulation of doxorubicin into liposomes
prepared in manganese chloride
In order to assess the role of the sulfate anion in mediating
precipitation of doxorubicin, drug loading in liposomes with
encapsulated MnCl2 was characterized. A solution of 300
mM MnCl2 (pH 3.5) was used to prepare DMPC/Chol
liposomes and following gradient formation (see Methods),
doxorubicin was added to achieve a final drug-to-lipid ratio
of 0.2:1 (wt/wt). Similar to results obtained when using
entrapped MnSO4 in the absence of A23187, doxorubicin
loading occurred optimally at 60jC and no loading was
observed at 20jC (Fig. 5A). The resulting drug-loaded
liposomes were opaque royal purple in colour. Under con-
ditions where MnCl2 loaded liposomes were incubated with
doxorubicin in the presence of A23187 (Fig. 5B), drug
loading was also achieved at 60jC; however, the resulting
liposome preparation had an orange appearance. Following
drug loading to achieve the maximum 0.2:1 drug-to-lipid
ratio (wt/wt), there was a time-dependent decrease in the
drug-to-lipid ratio from 0.2:1 (measured at 20 min) to less
then 0.15:1 (measured at 40 min).
Representative cryo-electron micrographs obtained from
the MnCl2 liposome formulation are shown in Fig. 6. These
images suggest that in the presence or absence of A23187,
the core of the drug-loaded liposomes have a stippled and
diffuse precipitate (Fig. 6IIA,IIB). The results suggest that
formation of the fibrous bundle, observed following A23187
Fig. 5. Doxorubicin encapsulation using liposomes prepared in 300 mM
manganese chloride, pH 3.5, and with the external buffer exchanged to
SHE, pH 7.5. Drug loading was measured in the presence (B) and absence
of the ionophore A23187 (A). The methods used were identical to those
described for the manganese sulfate loading procedure and are summarized
in the legend to Fig. 2 and Methods. Briefly, doxorubicin was added to
achieve a final drug-to-lipid ratio of 0.2:1 (wt/wt). Subsequently, the
samples were incubated at either 20jC (n), 40jC (.) or 60jC (E) and at
the indicated time points, the sample was passed through a 1 ml spin
column to separate free drug from encapsulated, which was quantitated as
described in Methods. The data points represent the mean drug-to-lipid
ratios obtained from three separate experiments and the error bars indicate
the standard deviation.
Fig. 4. cTEM images of DMPC/Chol (55:45) liposomes either before or
after drug loading achieving a final drug-to-lipid ratio of 0.2:1 (wt/wt). The
liposomes were prepared as described in Methods and loaded with
doxorubicin as summarized in Fig. 2. Briefly, the samples were incubated at
60jC for 30 min in order to facilitate >95% doxorubicin encapsulation.
cTEM images were obtained from liposome samples prior to drug addition
and from liposomes with encapsulated drug. All images are representative
of the entire sample. (Panel IA) DMPC/Chol liposomes prepared in 300
mM citrate, pH 3.5, and with the outside buffer changed to HEPES-buffered
saline, pH 7.5, as the exterior buffer. (Panel IIA) Same as those described
for IA except after liposomes have been loaded with doxorubicin. (Panel
IB) DMPC/Chol liposomes prepared in 300 mM MnSO4, pH 3.5, and with
the outside buffer changed to SHE, pH 7.5. (Panel IIB) Same as those
described in IB except after liposomes have been loaded with doxorubicin.
(Panel IC) DMPC/Chol liposomes prepared in 300 mM MnSO4, pH 3.5;
with the outside buffer changed to SHE, pH 7.5, and following addition of
the ionophore A23187. (Panel IIC) Same as those described in IC except
after liposomes have been loaded with doxorubicin. The bar in panel IA is
equivalent to 100 nm and all micrographs are shown at the same mag-
nification.
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mediated doxorubicin loading into liposomes prepared in
300 mM MnSO4 was due, in part, to the presence of the
sulfate anion. Osmotic gradients across liposomes influence
liposome shape and it should be noted that when preparing
the citrate and MnCl2 (300 mM citrate (580 mOsm/l) 300
mM MnCl2 (785 mOsm/l)) liposomes, there is an osmotic
gradient across the membrane (exterior solutions of HBS
(326 mOsm/l) and SHE (517 mOsm/l), respectively), which
results in the inward movement of water. This results in a
‘‘swelling’’ of the liposomes and thus they appear as round
structures (Figs. 4IA and 6IA). In contrast, the MnSO4-
loaded liposomes are hypoosmotic (300 mM MnSO4 (319
mOsm/l) and with respect to its environment SHE (517
mOsm/l)) and results in the movement of water to the
outside. Thus, these liposomes appear as oblong structures
(see Fig. 4IB,IC for comparison). Following addition of
A23187 (with the shuttling of the divalent cations out of
the liposomes) and doxorubicin loading, the liposomes
become even more elongated.
3.4. Assessment of the transmembrane pH gradient prior to
and following doxorubicin loading
One of the distinguishing features of the loading proce-
dure that relies on encapsulated MnSO4 is the absence of an
effective internal buffer. In fact, doxorubicin loading in the
absence of A23187 should result in a rapid dissipation of the
transmembrane pH gradient. Radiolabeled methylamine was
used as a pH-sensitive probe [3,10] to measure the pH
gradient across the liposomal formulations after exchanging
the exterior buffers and following doxorubicin uptake. As
noted in Methods, all liposomal formulations were prepared
in solutions with a pH of 3.5. Thus, following the external
buffer exchange, it was anticipated that the transmembrane
pH gradient would be approximately four units. Three
formulations were evaluated in these studies and the results
have been summarized in Fig. 7. Following the establish-
ment of the pH gradient, but prior to doxorubicin loading,
the formulations with encapsulated citrate (column 1),
MnSO4 (column 3), and MnCl2 (column 7) exhibited
measured transmembrane pH gradients of 3.4, 1.6, and less
than 0.18, respectively. Therefore, even in the absence of
drug loading or ionophore addition, the Mn-based formula-
tions had significantly smaller pH gradients. Following
addition of doxorubicin, the pH gradient of the citrate-based
formulation decreased from 3.4 (column 1) to 2.3 (column
2), a result that is consistent with previous reports demon-
strating doxorubicin-mediated decreases in the pH gradient
in these formulations [25].
Fig. 7. Measured transmembrane pH gradients prior to and following
doxorubicin loading under the various conditions as described in Figs. 2
and 5. The pH gradient was estimated through use of radiolabeled
methylamine as described in Methods. Radiolabeled methylamine was
added to liposomes after they were incubated at 60jC for 30 min either in
the presence or absence of doxorubicin. Doxorubicin was added to achieve
a final drug-to-lipid ratio of 0.2:1 (wt/wt). The samples include those based
on the citrate loading method (column 1), with doxorubicin (column 2); the
MnSO4-loading method (column 3), with doxorubicin (column 4). The
MnSO4-loading method with A23187 (column 5), with doxorubicin
(column 6); the MnCl2-loading method (column 7), with doxorubicin
(column 8) and the MnCl2-loading method plus the ionophore A23187
(column 9) with doxorubicin (column 10). The results represent the mean
pH gradient of three separate experiments and the error bars indicate the
standard deviation.
Fig. 6. cTEM images of DMPC/Chol (55:45) liposomes either before or
after drug loading, achieving a final drug-to-lipid ratio of 0.2:1 (wt/wt). The
liposomes were prepared as described in Methods and loaded with
doxorubicin as summarized in Fig. 5. Briefly, the samples were incubated at
60jC for 30 min in order to facilitate >95% doxorubicin encapsulation.
cTEM images were obtained from a liposome sample prior to drug addition
and from liposomes with encapsulated drug. All images are representative
of the entire sample. (Panel IA) DMPC/Chol liposomes prepared in 300
mMMnCl2, pH 3.5, and with the outside buffer changed to SHE, pH 7.5, as
the exterior buffer. (Panel IIA) Same as those described for IA except after
liposomes have been loaded with doxorubicin. (Panel IB) DMPC/Chol
liposomes prepared in 300 mM MnCl2, pH 3.5; with the outside buffer
changed to SHE, pH 7.5, and after the addition of the ionophore A23187.
(Panel IIB) Same as those described in IB except after liposomes have been
loaded with doxorubicin. The bar in panel IA is equivalent to 100 nm and
all micrographs are shown at the same magnification.
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In the absence of the ionophore, but following doxorubi-
cin loading, the Mn-containing formulations exhibited no
measurable transmembrane pH gradient (refer to Fig. 7,
columns 4 and 8). This result indicates, unequivocally, that
these doxorubicin-loaded preparations no longer maintain a
pH gradient and this is consistent with the fact that these
formulations have little or no ability to buffer against changes
in pH induced by drug loading. In contrast, the addition of
A23187 to either theMnSO4 (column 5) orMnCl2 (column 9)
containing liposome formulations resulted in generation of a
substantial pH gradient. As estimated using methylamine,
these pH gradients were approximately 4.0 and 1.8, respec-
tively. Even following doxorubicin loading, these two for-
mulations (columns 6 and 10) maintained pH gradients of 3.6
and 1.0, respectively.
3.5. Absorption and CD spectra of doxorubicin under
various conditions
In order to explore the role of Mn2 + ion complexation
with doxorubicin, and the associated influence of pH,
spectroscopic studies were completed. Doxorubicin (see
inset to Fig. 8) possesses a chromophore with multiple
k!k* and n!k* transitions rendering doxorubicin’s
electronic absorption and CD spectra sensitive to the depro-
tonation of the chromophore and the binding of metal ions
[26,27]. As shown in Fig. 8A, when the pH increases, there
is a visible bathochromic shift observed with two predom-
inant absorption bands appearing at 550 and 590 nm. This
spectral shift has been attributed to deprotonation of the
hydroxyls at the C(6) (pKa = 13.2) and C(11) (pKa = 10.16)
positions [27]. We observed a similar shift of the doxor-
ubicin spectra at a fixed pH (pH 8.0) following the addition
of MnSO4 (Fig. 8B). The observed bathochromic shift
resulted in two predominant absorption bands centered
around 542 and 581 nm. The shift was observed even in
the presence of 100 mM MnSO4. These results suggest that
in the presence of Mn2 + , the ion is potentially capable of
deprotonating the chromophore at the C(11)-OH and C(6)-
OH positions.
To further characterize the interactions of Mn2 + with
doxorubicin, CD spectra of doxorubicin-loaded liposomes
were obtained. The formulations evaluated include ones
where the drug was encapsulated using the citrate-based
and the manganese sulfate-based loading procedures. The
latter was completed in the absence and presence of
A23187. As shown in Fig. 8C, the CD spectra obtained
for encapsulated doxorubicin prepared using the citrate and
the MnSO4 plus A23187 loading methods were similar. This
result is likely due to the similar conformations doxorubicin
Fig. 8. Absorption spectra of doxorubicin at various pHs and concentrations
of MnSO4 as well as the CD spectra of doxorubicin-loaded liposomes. (A)
The absorbance spectra of an 86 AM doxorubicin solution at pH 6, 8, 9, 10,
11, and 13. The pH of each sample was maintained by either 100 mM MES
(pH 6), 100 mM HEPES (pH 8), 100 mM CHES (pH 9), 100 mM CAPS
(pH 10), 100 mM CAPS (pH 11) and 100 mM glycine + 100 mM NaCl (pH
13). The absorbance spectra were obtained immediately after drug
solubilization to minimize doxorubicin degradation. (B) Representative
absorption spectra of an 86 AM doxorubicin solution in the presence of
various concentrations of MnSO4 at pH 8. MnSO4(S) was added to 1 ml of
100 mM HEPES at pH 8 and vigorously vortexed, then doxorubicin was
added to obtain a final concentration of approximately 86 AM. The
solubility of MnSO4 at pH 8 is low and the formation of Mn(OH)2(S) is a
limiting factor, therefore absorption readings were taken immediately.
There was no visible precipitation in the sample within the time frame
required to obtain the spectra. (C) Representative CD spectra of
doxorubicin-loaded DMPC/Chol liposomes, where drug loading was
achieved using either the citrate or the manganese sulfateFA23187
loading procedures. Empty DMPC/Chol liposomes containing either 300
mM citrate or 300 mM manganese sulfate were analysed as controls and
showed Def 0 as a function of k= 300–800 nm (data not shown).
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assumes at an internal pH of < 5.5 (see Fig. 4IIA,IIC) within
liposomes containing citrate and sulfate, respectively. Using
CD analysis as a tool to evaluate doxorubicin, Fiallo et al.
[27] have attempted to assign specific absorption bands to
specific electronic transitions. These are summarized in
Table 1 and suggest that absorption bands appearing at
330 and 346 nm wavelengths correspond to a n!k*
transition at the C(12) position and a n!k* transition at
the C(5) position. The results in Fig. 8C indicate an inverse
of chirality at 330 nm for the citrate (De = 15.37) and the
MnSO4 plus A23187 (De = 6.94) loaded liposomes as
compared to doxorubicin encapsulated into the MnSO4
(De = 6.79) loaded liposomes in the absence of ionophore.
These results also indicate an inverse of chirality at 346 nm
for the citrate (De = 9.51) and the MnSO4 plus A23187
(De = 3.14) loaded liposomes as compared to the spectra
obtained for doxorubicin loaded into MnSO4 (De = 5.02)
liposomes without ionophore. En bloc, these observations
strongly suggest that in the presence of Mn2 + and an
internal pH of >7.0, doxorubicin complexes with the metal
ion, which interacts with the oxygen groups associated with
the C(11)–O  and C(12)MO positions as well as the
C(5)MO and C(6)-O  positions.
3.6. The influence of entrapped doxorubicin structure on
drug release from liposomes in vitro and in vivo
The loading methods described provide effective means
to prepare an encapsulated form of doxorubicin. The results
also suggest that one can control the chemical and physical
properties of the encapsulated drug by considering the use
of an entrapped transition metal, such as Mn2 + , and a
method whereby the drug-loaded liposome no longer exhib-
its a transmembrane pH gradient (pH 7.5 inside and out).
From a practical point of view, however, it is critical to
determine whether the loading methods used change drug
release attributes in vitro and in vivo. These studies have
focused, thus far, on liposomes prepared of DMPC/Chol, a
lipid composition selected specifically because it is known
that doxorubicin readily permeates across this lipid bilayer,
as opposed to formulations prepared with DSPC/Chol,
which retain drug for extended time periods both in vitro
and in vivo. It is also important to recognize that others have
indicated that formation of the doxorubicin citrate or SO4
precipitate as well as maintenance of a transmembrane pH
gradient (inside acid) are necessary if doxorubicin is to be
well retained within a liposome following drug loading
[7,18]. Therefore, it was anticipated that those formulations
prepared in a manner that did not facilitate formation of the
fibrous bundles and which resulted in substantial dissipation
of the pH gradient would not be able to retain the entrapped
doxorubicin. As shown in Fig. 9 (in vitro data) and Fig. 10
(in vivo data), this was not observed when the liposomal
lipid composition was DMPC/Chol (55:45, mole ratio). For
the in vitro assay, doxorubicin-loaded DMPC/Chol lipo-
somes (0.2:1 drug-to-lipid ratio, wt/wt), were prepared using
the citrate or the manganese-sulfate based loading proce-
dures (with and without A23187), and diluted with fetal
bovine serum and incubated at 37jC (Fig. 9). Changes in
drug-to-lipid ratios, measured at various time points over a
Table 1
The differential molar CD absorption De (M 1 cm 1) of doxorubicin-encapsulated liposomes
Loading procedures k!k* (z-axis) n!k *C(12)MO n!k *C(5)MO k!k* ( y-axis)
300 nma 330 nm 346 nm 448 nm 513 nm 542 nm
Manganese sulfate (De)  1.08 6.79 5.02  6.84 8.60 35.20
Citrate (De) 0.062  15.37  9.51 18.85 10.13 13.63
Manganese sulfate (De) with A23187  0.94  6.94  3.14 12.30 2.60 4.03
Doxorubicin was loaded into liposomes using the citrate, the manganese sulfate or the manganese sulfate with A23187 procedure as described in Methods.
Specific wavelengths correspond to potential electronic transitions undergone by doxorubicin following encapsulation.
a Wavelengths adapted from CD bands of anthracyclines in 0.05 M HEPES and 0.1 M KCl [35].
Fig. 9. The release of doxorubicin from DMPC/Chol (55:45) liposomes
loaded using the procedures described in Fig. 2. Drug release was
determined in vitro as described in Methods, where liposomes were loaded
with doxorubicin to achieve a final drug-to-lipid ratio of 0.2:1 (wt/wt) using
the citrate (n), the manganese sulfate (.), or the manganese sulfate loading
procedure with the A23187 ionophore (E). After drug encapsulation, each
sample was mixed with fetal bovine serum (final serum concentration of
80% and lipid concentration of 2 mg/ml) and incubated at 37jC. At the
indicated time points, the drug and liposomal lipid concentrations were
measured after fractionating samples on a 1 ml spin column as described in
Methods. These data were used to calculate a drug-to-lipid ratio at various
time points. Data points represent the mean of data obtained from three
separate experiments and the error bars indicate the standard deviation for
each data point.
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72-h time course, indicated that all three formulations
exhibit comparable drug release profiles. It can be suggested
on the basis of these in vitro data, that more drug is released
from the manganese sulfate-loaded liposomes prepared in
the absence of A23187. This difference in drug release,
however, can be accounted for by an observed 20% loss in
encapsulated drug measured at the first time point (4 h after
dilution into the serum-containing buffer).
Similar results were obtained in vivo following i.v.
administration of the DMPC/Chol formulations (Fig. 10),
where plasma elimination measurements for liposomal lipid
(Fig. 10A) and drug (Fig. 10B) can be used to calculate
changes in drug release (Fig. 10C). These in vivo studies
attempted to differentiate between the release of doxorubicin
from DMPC/Chol liposomes where the drug exists as
doxorubicin bundles (citrate loading technique) or a man-
ganese complex (MnSO4 procedure without A21387). Fol-
lowing i.v. injection in CD-1 mice (lipid dose of 100 mg/kg
and drug dose of 20 mg/kg), measurements of plasma
liposomal lipid levels (Fig. 10A) over 24 h indicated that
the two formulations were eliminated from the plasma
compartment at identical rates. Assessments of plasma
doxorubicin levels (Fig. 10B) indicated that there were
significantly lower levels of drug in the plasma at the 1
and 4 h time points when the drug was administered in the
MnSO4 liposomes loaded with drug in the absence of
A23187 (two-tailed P values were < 0.01 and 0.001,
respectively). Consistent with the in vitro results, there
was a rapid 20% loss of drug from these liposomal for-
mulations within 1 h after administration. Subsequently, the
rates of drug release from the two liposomal formulations
were comparable (Fig. 10C). This result was unexpected
considering that the two liposomal formulations exhibited
remarkably different interior pHs; however, this result may
just be a reflection of the increased permeability of the
DMPC/Chol formulations. Under the time frame assessed,
this formulation did not exhibit pH-dependent differences in
drug release rates.
In order to demonstrate that drug release rates are
dependent on liposomal lipid composition, the studies sum-
marized in Fig. 10 were repeated for formulations prepared
with DSPC/Chol liposomes. The loading attributes of the
two different liposomal formulations were comparable in
that >95% drug loading was achieved in within 10 min
provided the liposomes were incubated with drug at 60 jC
(results not shown). The results of this study are summar-
Table 2
Percent of encapsulated doxorubicin retained in liposomes following i.v.
administration of DMPC/Chol and DSPC/Chol liposomes loaded with drug
using encapsulated 300 mM citrate (pH 3.5) or the MnSO4 method without
the ionophore A23187a
Formulation Time following administrationb
1 h 4 h 24 h
DMPC/Chol–Citrate 100F 3.9c 75F 5.5 27F 1.8
DMPC/Chol–MnSO4 100F 5.5 63F 7.3 21F1.3
DSPC/Chol–Citrate 100F 5.4 95F 10.9 100F 3.8
DSPC/Chol–MnSO4 100F 6.4 73F 6.1 53F 3.5
a After drug loading, the latter formulations exhibited a transmembrane
pH gradient of less than 0.5 units while the former exhibited pH gradients in
excess of 3 units.
b As described in Fig. 10, following i.v. administration in CD1 mice,
plasma concentrations of liposomal lipid and doxorubicin are measured at
the indicated time points. These data are then used to calculate the drug-to-
lipid ratio in the liposomes within the plasma compartment, a parameter that
is used as a measure of in vivo drug release.
c The percent drug-to-lipid ratio was calculated using the measured
drug-to-lipid ratio determined 1 h after administration as a value indicative
of 100%.
Fig. 10. The release of doxorubicin from DMPC/Chol (55:45) liposomes,
following i.v. administration into female CD1 mice. Liposomes were loaded
with drug to achieve a final drug-to-lipid ratio of 0.2:1 (wt/wt) using the
citrate (n) or the manganese sulfate (.) procedures as previously described
in Methods. Doxorubicin-loaded liposomes were adjusted to a concen-
tration such that the lipid dose of 100 mg/kg could be administered in an
injection volume of 200 Al. At the indicated time points following injection,
blood samples were obtained and plasma was prepared as described in
Methods. Plasma lipid levels (A) were determined from measurements of
3H-CHE as a liposomal lipid marker. The level of doxorubicin fluorescent
equivalents (B) was measured in plasma using the drug extraction
procedure described in Methods. The drug-to-lipid ratios (C) were
calculated on the basis of the data shown in panels A and B. Each data
point represents the mean drug-to-lipid ratio obtained from at least six mice
and the error bars indicate the standard deviation of each data point.
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ized in Table 2. Drug release attributes of the DMPC/Chol
and DSPC/Chol formulations were estimated by calculating
the percent change in the measured drug-to-lipid ratio
determined at 1 h. As indicated by the data in Fig. 10C,
the change in drug-to-lipid ratio determined for the DMPC/
Chol formulations are comparable, regardless of whether the
drug was encapsulated using the citrate-based methodology
or the MnSO4 without ionophore. In contrast, results
obtained with DSPC/Chol liposomes clearly demonstrate
that the rate of drug release is more rapid when the drug is
encapsulated using the MnSO4 (without ionophore) method.
At the 24 h time point, liposomes prepared using this
methodology exhibited a drug-to-lipid ratio of 0.09:1 (wt/
wt) as compared to measured values of 0.18:1 (wt/wt)
obtained for formulations prepared using the citrate method.
4. Discussion
Doxorubicin has a broad spectrum of anticancer activity
and is used to treat a variety of solid tumors as well as
lymphomas and acute leukemias. One of many problems
attributable to the use of this drug in its free form is its ability
to engender cardiac toxicity, a toxicity that limits the amount
of drug that can be given chronically [28,29]. Eliminating
cardiotoxicity has been attempted with methods such as (1)
alternative dosing [30], (2) pre/co-administration of free
radical scavengers [31], (3) the development of semisyn-
thetic derivatives [32,33] or (4) by liposomal encapsulation
[34–36]. The latter approach provides a means of altering the
biodistribution of drug whereby there are significant reduc-
tions in drug accumulation in cardiac tissues. There are now
two liposomal–doxorubicin formulations approved for
human use (Doxilk or Caelyxk and Myocetk). Despite
the clinical development of this technology, there are still
important questions to be addressed about the physical state
of the entrapped drug. We believe that this information will
be essential when considering the development of other
liposomal anthracyclines as well as other drug classes.
Consistent with previous studies, the results presented
here support the concept that drugs encapsulated in lip-
osomes through use of ion gradients can form precipitates
within the liposome. Our studies, however, clearly suggest
that the nature of the entrapped precipitate is dependent on
the internal pH and chemical composition. Importantly,
these data also indicate that for a drug like doxorubicin,
the resulting formulation can retain entrapped drug even
under conditions where there is little or no residual pH
gradient. Investigations focused on determining the factors
controlling doxorubicin release from liposomes provide
conflicting viewpoints. Certain studies indicate that high
trapping efficiency, high drug-to-lipid ratios and stable drug
retention are linked to the maintenance of a large pH
gradient [7,13,37]. A reasoned explanation for these results
was that as doxorubicin was encapsulated, the pH (inside)
increased due to the consumption of protons as the neutral
drug became protonated. In turn, drug retention was
thought to hinge on the equilibrium between the protonated
and nonprotonated forms of doxorubicin. It was concluded
that if a low interior pH were maintained, more doxorubicin
would be in the protonated (charged) and thus in a
membrane-impermeable state. In the case of liposomes
prepared with DMPC/Chol, the in vivo release rates for
preparations with and without a measurable pH gradient are
essentially the same. For DSPC/Chol liposomes, there is a
measurable change in the rate of drug release following i.v.
administration, where drug release is greater for those
formulations that lack a pH gradient. These observations
would suggest that when liposomes are incubated at a
temperature above the bulk phospholipid Tc, drug release
occurs in a time frame that is not substantially influenced
by the internal pH. Results obtained with DSPC/Chol
liposomes, however, allow interior pH associated differ-
ences in in vivo drug release rates to be discerned. Perhaps
most interesting, the methods described here provide a
means to develop liposomal drug formulations where drug
is encapsulated through very distinct mechanisms and
chemical reactions.
It has been well recognized by those using methods of
drug loading that rely on ion gradients that drug accumu-
lation levels often exceed that which would be predicted on
the basis of ion redistribution according to the Henderson–
Hasselbalch equation [7,9,13,25]. In the case of the anthra-
cycline doxorubicin, these data have been explained by
mechanisms involving membrane partitioning and/or drug
precipitation [15–18]. It is well established, for example,
that doxorubicin at concentrations of >30 mg/ml, in the
presence of ammonium sulfate [15] or citrate [17], floccu-
lates as a consequence of the formation of fibrous structures.
cTEM studies indicated that the doxorubicin precipitate
consisted of fibrous-bundle aggregates in both citrate- and
sulfate-containing liposomes, with electron micrographs
comparable to those shown here (Figs. 4). In terms of the
physical state of doxorubicin, it has been proposed that the
planar aromatic anthracycline rings stack longitudinally to
form linear fibres within both citrate and sulfate-containing
liposomes [16]. These fibres are aligned in a hexagonal
arrangement to form bundles, with approximately 12–60
fibres per bundle. It was noted by these investigators that
doxorubicin–citrate aggregates appear mostly as linear or
curved structures (interfibre spacing was approximately 30–
35 A˚). Similarly, doxorubicin–sulfate aggregates are pro-
posed to consist of rigid linear fibre bundles (interfibre
spacing estimated to be approximately 27 A˚). It was
proposed that the sulfate anion, which is smaller than the
citrate anion, might form a tighter packing arrangement
resulting in decreased flexibility. As noted here under
conditions where doxorubicin precipitates formed, the for-
mulation containing citrate exhibited both curved and cir-
cular electron dense structures that caused a slight distortion
of the liposome shape (Fig. 4IIA). In contrast, the sulfate-
containing formulations exhibited primarily linear precip-
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itates and a significant elongation of the liposome (Fig.
4IIC). These differences in liposome shape appear to have
little or no impact on the plasma liposomal lipid elimination
profiles obtained following i.v. administration (see Fig.
10A).
Our studies indicate that doxorubicin-loaded liposomes
prepared using the MnSO4- and MnCl2-based procedures in
the absence of A23187 are strikingly different than doxor-
ubicin-loaded liposomes using the citrate procedure. Fol-
lowing drug loading, both of these formulations were a
royal purple colour, as compared to the citrate-loaded
preparations that are orange in appearance. Cryo-electron
micrographs of the purple liposomal formulations indicated
the appearance of an electron dense precipitate without any
distinguishable crystalline structure. The resulting drug-
loaded liposomes (prepared in the absence of A23187) also
exhibited little or no transmembrane pH gradient. As shown
in Figs. 9 and 10, these differences had little impact on drug
retention attributes within the DMPC/Chol formulation but
significant differences in drug release were observed for the
DSPC/Chol formulation (Table 2). It was noted that on
addition of the ionophore A23187 to these formulations, the
encapsulated drug was in a form where it could readily
assemble into fibre bundles, particularly in the MnSO4-
containing liposomes where addition of the ionophore gen-
erates a >2.5 unit pH gradient (inside acidic). Thus, the
encapsulated drug is free to assume different chemical
structures depending on the pH and the chemical composi-
tion within the liposomes.
Several studies have examined the role of transition metal
anthracycline interactions [26,38,39]. These studies, which
relied on a variety of spectroscopic methods, concluded that
primary metal binding involved the deprotonation of the
hydroxy anthraquinone moieties and the associated forma-
tion of a six-membered chelate. The absorbance spectra of
doxorubicin in various concentrations of MnSO4 clearly
showed a shift to higher wavelengths (lower energy). These
absorption bands closely mimic those bands obtained fol-
lowing the deprotonation of doxorubicin at pH values above
10. Based on the spectroscopic information gathered from
studies of multiple anthracycline derivatives [27,39], our
data support the proposal that Mn2 + is interacting at both the
C(11) O and C(12)MO positions and the C(5)MO and
C(6)-O  positions. Other investigators looking at the bind-
ing of Fe2 + to anthracyclines have observed the deprotona-
tion at the C(11)–OH and the C(6)–OH positions and the
bathochromic shift from 480 to either 550–590 or 580–615
nm, respectively, for a variety of anthracycline derivatives
including doxorubicin, pirarubicin, daunorubicin and idar-
ubicin [39]. The strong CD band centred around 573 nm in
the manganese doxorubicin-loaded liposome spectra con-
firms our belief that Mn2 + is complexed within these
proposed coordination sites. Similar to the studies reported
here, these investigators also reported that metal–anthracy-
cline complexation resulted in a colour change from orange
to blue-violet.
Complexation involving anthracyclines generally accom-
panies a theoretical increase of protons or a decrease in
observed pH. This is not consistent with the results pre-
sented in Fig. 7, which clearly demonstrate that metal ion
complexation does not result in formation of a pH gradient.
It is suggested here that manganese complexes with doxor-
ubicin in the following manner:
MnSO4 ðaqÞfMn2þðaqÞ þ SO24 ðaqÞ ð1Þ
In water, the transition metal cations are always present as
complex-hydrated ions;
Mn2þðaqÞ þ 6H2OfMnðH2OÞ2þ6 ðaqÞ ð2Þ
The hydrated transition metal cations behave as weak acids
in water,
MnðH2OÞ2þ6 ðaqÞfHþ þMnðH2OÞ5ðOHÞ1þðaqÞ ð3Þ
Ka of MnðH2OÞ2þ6 ðaqÞ ¼ 3 1011
Because the hydrated manganese cation behaves as a weak
acid and can dissociate to Mn(H2O)5(OH)(aq)
1 + , it most likely
coordinates with the bidentate site offered by the C(11)–OH
and C(12)MO positions or the C(5)MO and C(6)–OH posi-
tions neutralising the displaced hydrogen ion.
In summary, our studies have characterized the interac-
tions between the transition metal manganese and doxor-
ubicin, an interaction that promotes the accumulation of
drug inside liposomes that contain this metal. The resulting
drug-loaded liposome is unique in that the complexed drug
is maintained in a form that is distinct from that identified
for loading methods relying on maintenance of a pH
gradient and formation of a citrate- or sulfate-based precip-
itate. The resulting liposomal drug formulation lacks a pH
gradient, but still allows for effective drug retention attrib-
utes following i.v. administration. We are most excited,
however, because the mechanism of drug loading occurs
in a manner that is clearly distinct from methods involving
use of pH gradients and it may be applicable to other drugs
that possess coordination sites capable of complexing tran-
sition metals.
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